PATENT

## 10997 U.S. PTO 09/966724 10/01/01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	Prior Group Art Unit: 1632
KINZLER et al.	Prior Examiner: S. Priebe
Continuation of Serial No. 08/390,474	) ) )
Filed: October 1, 2001	Atty. Dkt. No. 01107.00193

FOI: AMPLIFICATION OF MDM2 GENE OF HUMAN MDM2 GENE IN HUMAN TUMORS

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Pursuant to the duty of good faith and candor as set forth in 37 C.F.R. § 1.56(a) Applicant submits herewith a Form PTO 1449. Since these documents were previously cited in Application Serial No. 08/390,474 no copies are being supplied herewith.

Applicant respectfully requests that the Examiner consider and enter these documents into the file of the above-identified application. No fee is believed to be due to ensure consideration and entry of the cited documents by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,

Sarah A. Kagan Registration No. 32,141

BANNER & WITCOFF, LTD. 1001 G Street, N.W., 11<sup>th</sup> Floor Washington, D.C. 20001 TEL: (202) 508-9100

FAX: (202) 508-9299

Dated: October 1, 2001

PTO/SB/08A (08-00)

Approved for use through 1031/2002. OM8 0953-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of internation unless a contains a valid DMB control number O
to from 1449APTO

Application Number

TBA/Continuation of 08/390,474

Substitute for form 1449A/PTO Application Number INFORMATION DISCLOSURE September 28, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor KINZLER et al. Prior Group Art Unit 1632 (use as many sheets as necessary) Prior Examiner Name S. Priebe 01107.00193 of 2 Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, orly and/or country where published.	T²
		Fakharzadeh, et al., "Tumorioenic Potential Associated with Enhanced Excression of a Gene Tht is Amplified in a Mouse Tumor Cell Line", The EMBQ Journal, 10(6):1565-1569 (1991)	
		Hinds, et al., "Mutant p53 DNA Clones From Human Colon Carcinomes Cooperate with Res in Transforming Parkey Res Colon A Companison of the Hot Spot Mutant Phenotypes", Call Growth & Differentiation, 1:561-580 (1990)	
/BW/		Romkes, et al., "Cloning and Expression of cDNA for Multiple Members of the Human Cytochrome P450IIC Subfamily", <u>Blochemistry</u> , 30(13):3247-3255 (1991)	
***************************************		Memore, et al., The MOM2 Geogeon Broduct Forms a Complex with the o53 Protein and Inhibits n53-Mediated Transactivation." Cell. 69:1237-1245 (1992)	
		Oliner, et al. "Amolification of a Gene Encoding a n53-Associated Protein in Human Sarromas". Nature. 358:80-83 (1992)	
****		Ladanyi, et al., "MDM2 Gene Amplification in Metastatic Osleosarcoma", <u>Cancer Research</u> , 53:2231-2234 (1993)	
		Oliner, et al. "Opcopretain MOM2 Conceals the Aciantion Domain of Tumous Supersons p53", Nature, 362(6423):857-860 (1993)	
		Cahilly, et al., "Molecular Analysis and Chromosomal Manoing of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line", Somatic Cell and Molecular Genetics, 13(3):235-244 (1987)	
		Hodgoon, <u>East Spin, Tree, 441</u> , 5(3), 1985, 433 400	
		Uhimann et al., <u>Chem. Rev.</u> , 90(4), 1990, 544-584	
		Converter at., <u>1112</u> , 10(5), 1994, 174-178	
		Leach, et al. "a53 Mutation and MDM2 Amplification in Human Soft Tissue Sarcomas", Cancer Research, 53.2231-2234 (1993)	
			_

Signature	Considered
	to the control of the conformation of the conf
EVAMINED: Initial if reference considered	thether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

Date

Examiner

and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Nov Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patient and Trademark. Office. Weakington, DC 20231. DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.

(use as many sheets as necessary)

of

Sheet

PTO/SB/08A	
------------	--

(08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

> S. Priebe 01107.00193

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known TBA/Continuation of 08/390,474 Application Number INFORMATION DISCLOSURE Filing Date September 28, 2001 STATEMENT BY APPLICANT First Named Inventor KINZLER et al. Group Art Unit 1632

Examiner Name

Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T²
-		Warayanan at al., <u>Smax, m., 1992, 7(8), 55</u> 9-594	
*******		Lorano et al., <u>Nature</u> , 951, 1991, 459 456	
		Marshall Science 269 1995 1050-1055	
*****		Stein et al., <u>Science</u> , 201, 1993, 1004-1012	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Wu-Pong, Pharm, Tech., 18, 1994, 102-114	
5000000000		Miller et al., <u>FASEB</u> , 9, 1995, 190-199	
		Rojanasakul, <u>AB, Drug, Dey, Rev.,</u> 10(1990), 110-131	
2000may		Miller, <u>I Mart Chem.</u> , 36(14):1423-1437, 1993	

Signature /Brian Whiteman/ Considered 05/28/2008	Examiner Signature	/Brian Whiteman/		05/28/2008
--	-----------------------	------------------	--	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Child Information Officer, U.S. Patent and Trademark

Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.